The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
After receiving haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) some patients may also receive posttransplant cyclophosphamide (PTCy) as a graft-versus-host disease (GvHD) prophylaxis. However, it remains uncertain how patients who receive haplo-PBSCT and PTCy are impacted by CD34+ cell dose from their donor graft.
Here, we summarize an article by Maruyama et al.1 published in Blood Cells, Molecules and Diseases evaluating how CD34+ cell dose impacts patient outcomes after haplo-PBSCT with PTCy treatment.
Figure 1. Survival outcomes at 3 years after haplo-PBSCT*
GRFS, graft-versus-host disease-free relapse-free survival; haplo-PBSCT, haploidentical peripheral blood stem cell transplantation; OS, overall survival; PFS, progression-free survival.
*Data from Maruyama, et al.1
Table 1. Outcomes of both groups after haplo-PBSCT*
|
Haplo-low |
Haplo-high |
p value |
---|---|---|---|
Median time to achieve an absolute neutrophil count of ≥0.5 × 109/L |
17 days |
17 days |
p = 0.832 |
Median time to achieve a platelet count of ≥50 × 109/L |
33 days |
29 days |
p = 0.466 |
NRM (95% CI), % |
0.0 |
19 |
p = 0.075 |
Cumulative incidence of Grade 2-4 aGvHD (95% Cl), % |
40.0 |
16.7 |
p = 0.058 |
Cumulative incidence of moderate-to-severe cGvHD (95% CI), % |
13.3 |
17.6 |
p = 0.720 |
aGvHD, acute graft-versus-host disease; cGvHD, chronic graft-versus-host disease; CI, confidence interval; haplo-PBSCT, haploidentical peripheral blood stem cell transplantation; NRM, non-relapse mortality. |
Key learnings |
---|
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content